Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1. (BENEMCOR)

NCT01716026 Phase 3 COMPLETED

The purpose of this protocol is to determine wether the initial protocol in the treatment of subfoveal choroidal neovascularization associated to High Myopia with bevacizumab intravitreal injections is more effective when using 3 doses vs using 1 single dose in the load period

Details

Lead sponsor	Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Phase	Phase 3
Status	COMPLETED
Enrolment	66
Start date	2012-10
Completion	2018-04

Conditions

• Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia

Interventions

• Bevazizumab intravitreal injection

Primary outcomes

• Early Treatment Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity — 1 Year
  Differences in best corrected visual acuity in the exit visit compared to the one obtained at screening visit
• Retinal thickness — 1 Year
  Retinal thickness assessed by Spectral Domain Optical Coherence Tomography
• Number of total injections during study — 1 Year
  Total count of bevacizumab intravitreal injections during the whole study

Countries

Spain